Despite advancements in new treatments, management of older patients with acute lymphoblastic leukaemia (ALL) remains an unmet medical need. With increasing age, ALL patients have a significantly lower CR rate, higher early mortality and relapse rate, and poorer survival compared to younger patients. This is attributed to a higher prevalence of adverse prognostic factors among older individuals and reduced tolerance to chemotherapy. Progress has been made in tailoring moderately …